Strong Fourth Quarter Performance
Achieved high single-digit constant currency revenue growth of 8% and low teens adjusted EPS growth of 13% in Q4 2024. Non-GAAP EPS was $4.10, reflecting a 13% growth, and adjusted EPS grew 22% excluding FX impact.
Pharma and Academic Segments Lead Growth
Pharma sales grew 10% in Q4, with strong growth in Europe and Asia. Academic and Government segment grew 16%, driven by 35% growth in Asia and 20% growth in Europe.
New Product Success
Alliance iS constituted 20% of HPLC revenue in Q4, and Xevo TQ Absolute system unit sales grew 40% year-over-year, constituting 50% of tandem quad revenue.
PFAS Testing Market Leadership
PFAS revenue grew over 40% in Q4 and for the year, outpacing the market, which is estimated to grow at 20% annually.
Strong Full-Year Financials
Full-year non-GAAP EPS was $11.86, reflecting 1% growth despite a 5% decline due to FX. Recurring revenue grew 6% for the year.
Growth in Europe and India
Europe grew 11% in Q4, and India maintained high growth with over 25% for the year, contributing 70 to 100 basis points to overall growth.